CGRP Education & Research Forum
Already a member? Become a member Register
youtubeLinkedIn
News

Long-term data reinforce Aimovig (erenumab) efficacy

Long-term analyses from pivotal studies of Aimovig (erenumab) have demonstrated sustained efficacy at 1-year follow-up. During the 52-week open label extension (OLE) of a Phase 2 study of erenumab in patients with chronic migraine, two thirds of participants sustained conversion or converted to episodic migraine (NCT02174861/NCT02066415).1 Greater reductions in monthly migraine days (MMD) and higher …

Read more »

Expanded data support Emgality (galcanezumab) in episodic cluster headache

Emgality (galcanezumab) has been shown to improve episodic cluster headache across a range of parameters at week 3 of treatment.1 Galcanezumab 300 mg significantly reduced weekly cluster headache frequency compared to placebo at weeks 1-3, with an accompanying significantly greater proportion of patients achieving a 50% reduction in weekly cluster headache attacks at week 3 …

Read more »

Ajovy (fremanezumab) efficacy and safety maintained over 12 months

Monthly and quarterly treatment with Ajovy (fremanezumab) reduces mean monthly migraine days over 12 months in both episodic and chronic migraine, according to long-term data on 1890 patients, of whom 1278 had completed previous placebo-controlled studies of fremanezumab and 312 were new patients (Table 1).1 Further data showed that response rates at month 12 were …

Read more »

Eptinezumab consistently demonstrates rapid onset of migraine prevention

Eptinezumab has consistently demonstrated rapid onset of migraine prevention on day 1 of treatment, and benefits maintained through to week 4, across four double-blind, placebo-controlled randomised trials.1 In the phase 2 and 3 trials in episodic and chronic migraine, eptinezumab was associated with reductions in migraine compared to pre-treatment screening. In the two trials of …

Read more »

Ubrogepant well tolerated in acute migraine treatment studies

Ubrogepant was well tolerated following intermittent, high frequency dosing in a Phase 1 double-blind, parallel-group study in healthy volunteers aged 18-50 years with no significant medical history and normal hepatic function (Table 1).1 Patients were randomised to ubrogepant 100 mg on two consecutive days followed by two consecutive days of placebo, alternating for 8 weeks, …

Read more »

Oral atogepant significantly reduces migraine days

Oral atogepant significantly reduced mean migraine days (MMD) across all dosing schedules in a Phase 2b/3 study of migraine prevention. In the randomised, double-blind, placebo-controlled study (NCT02848326), 834 patients were randomised to one of five dosing regimens, and 71.9% had never taken preventive migraine therapy. Mean baseline migraine days were 7.67 (SD=2.49), and mean change …

Read more »

Emgality (galcanezumab) benefits reported in both low- and high-frequency migraine headache

Pooled data from the EVOLVE 1 and 2 studies of Emgality (galcanezumab) have shown the benefits of treatment in patients with both low- and high-frequency episodic migraine (4-<8 vs 8-14 monthly migraine headache days [MMHD]). Galcanezumab 120 mg and 240 mg demonstrated statistically significant reductions in MMHDs in both the low- and high-frequency subgroups, compared …

Read more »